Ind-Swift Laboratories Limited (INDSWFTLAB) Financial History

Name: Ind-Swift Laboratories Limited (INDSWFTLAB) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Ind-Swift Laboratories Limited (INDSWFTLAB) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Manimajra, India with about 1,388 employees. Its market capitalization is roughly ₹32 billion. In the fiscal year ended 2026-03-31, INDSWFTLAB reported ₹6.3B in revenue and ₹431M in net income.

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally.

Interactive charts & full statements →

INDSWFTLAB Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹6.3B	₹5.6B	₹17.1B	₹12.1B	—
Gross Profit	₹2.8B	₹2.2B	₹7.1B	₹4.4B	—
Operating Income (EBIT)	(₹48M)	(₹416M)	₹2.4B	₹1.8B	—
Net Income	₹431M	₹2.5B	₹5.4B	₹476M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INDSWFTLAB Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	₹1.9B	₹1.7B	₹1.5B	₹1.5B	₹1.6B	—
Gross Profit	₹1.1B	₹1.1B	₹806M	₹750M	₹852M	—
Operating Income (EBIT)	₹258M	₹124M	(₹47M)	(₹55M)	₹25M	—
Net Income	₹247M	₹151M	₹95M	₹80M	₹88M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INDSWFTLAB Free Cash Flow History

INDSWFTLAB Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹16.7B	₹14.4B	₹14.6B	₹18.2B	—
Total Liabilities	₹2.9B	₹2.7B	₹6.5B	₹11.4B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive INDSWFTLAB viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

4577 · Daito Pharmaceutical Co.,Ltd. — JPY 38 billion
GALD · Galderma Group AG — CHF 37 billion
SOLARA · Solara Active Pharma Sciences Limited — ₹36 billion
4595 · Mizuho Medy Co.,Ltd. — JPY 33 billion
9273 · Koa Shoji Holdings Co.,Ltd. — JPY 32 billion
MEGA · Mega Lifesciences Public Company Limited — THB 31 billion
SDZ · Sandoz Group AG — CHF 30 billion
2096 · Simcere Pharmaceutical Group Limited — HK$29 billion

← INDS All “I” companies INDTERRAIN →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.